Edwards Lifesciences Corporation

Total Valuation

Edwards Lifesciences Corporation carries a market capitalization of 51.76B, placing it among publicly traded companies globally. Its enterprise value stands at 48.72B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Edwards Lifesciences Corporation currently has 576.60M shares outstanding.

Valuation Ratios

Edwards Lifesciences Corporation trades at a trailing price-to-earnings ratio of 52.23. The price-to-sales ratio is 8.06, and the price-to-book ratio stands at 4.91.

Enterprise Valuation

On an enterprise value basis, Edwards Lifesciences Corporation trades at an EV/EBITDA multiple of 24.42 and an EV/FCF ratio of 28.32. The EV/Sales ratio of 7.48 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 26.63 provides insight into valuation relative to core operating earnings.

Financial Position

Edwards Lifesciences Corporation maintains a current ratio of 4.52, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Edwards Lifesciences Corporation posts a return on equity of 9.50 and a return on invested capital of 2.45.

Taxes

Over the trailing twelve months, Edwards Lifesciences Corporation has paid 439.00M in income taxes, reflecting an effective tax rate of 84.46.

Stock Price Statistics

Edwards Lifesciences Corporation's stock has gained approximately 12.08079% over the past 52 weeks. The 50-day moving average sits at 89.64, while the 200-day moving average is 84.95.

Income Statement

Over the trailing twelve months, Edwards Lifesciences Corporation generated 6.51B in revenue and converted that into 1.00B in net income, yielding earnings per share of 1.68. EBITDA reached 2.00B, while operating income came in at 1.83B.

Balance Sheet

Edwards Lifesciences Corporation holds 4.25B in cash and equivalents against 704.40M in total debt, resulting in a net debt position of -2.31B. Total book value stands at 10.62B, with working capital of 5.31B providing operational flexibility.

Cash Flow

Edwards Lifesciences Corporation produced 1.72B in operating cash flow over the past twelve months.

Margins

Edwards Lifesciences Corporation operates with a gross margin of 77.84, reflecting its pricing power and cost economics. The operating margin of 28.09 and net profit margin of 15.43 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Edwards Lifesciences Corporation's most recent stock split took place on June 1, 2020 with a 1:3 split ratio.

Scores

Edwards Lifesciences Corporation posts an Altman Z-Score of 13.73, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.